Cybin Inc. (NEO: CYBN) on Right Path; Johns Hopkins Study Shows Psilocybin Positive Impact on Major Depression
Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depressionMost participants reported improvements; half experienced remission after only four weeksAs an early entrant in the field, Cybin looks well placed to capitalize on growing traction that psychedelics gain as potential treatment of mental health conditions Only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in depressive…